BioWorld - Saturday, August 19, 2023 See today's BioWorld Home » Dynavax Restarting Tolamba Program In Ragweed; Gets $30M X ...

Dynavax Reports Interim TOLAMBA Ragweed Allergy Results From DARTT Trial Insufficient Ragweed Allergic Disease in Placebo and Treated Groups Prevent Measurement of Therapeutic Effect BERKELEY ...

SAN FRANCISCO (MarketWatch) -- Dynavax Technologies Corp. DVAX, +1.38% after Wednesday's closing bell said results from a 2-year Phase II/III clinical trial of Tolamba for ragweed allergy ...

LONDON (MarketWatch) -- Dynavax Technologies Corp. DVAX, -1.77% said results from its Phase 2/3 trial of Tolamba, a ragweed allergy treatment, were encouraging and suggested that Tolamba has ...

Dynavax Technologies Corp <DVAX.O> said it would stop developing its experimental ragweed allergy drug, Tolamba, after it failed to meet the main goal of a mid-stage clinical trial, sending its ...

The initiation of dosing in the TOLAMBA chamber study triggered therelease of additional funding to Dynavax pursuant to the loan agreement, aswell as the issuance of warrants to Deerfield and its ...

BERKELEY, Calif., Nov. 12 Dynavax TechnologiesCorporation (Nasdaq: DVAX) presented yesterday a detailed analysis of datafrom the company's large-scale DARTT (SAR09) trial evaluating TOLAMBA(TM ...

The most recent phase 2b trial data on Tolamba show that one 6-week course significantly relieved nasal symptoms through at least 2 allergy seasons; the mechanism of action needs to be further ...

If the Tolamba program is discontinued, Dynavax has no obligation to repay up to $9 million of the funds to Deerfield that are set apart for the program, the company said. Sign up here.

BERKELEY, Calif.-- (BUSINESS WIRE)--May 16, 2008 - Dynavax Technologies Corporation (Nasdaq:DVAX) today reported primary endpoint data from a chamber study of TOLAMBA (TM) that showed a measurable ...

By Susan L. Thomas – Jan 20, 2006UpdatedJan 20, 2006, 2:22pm PST ...